Stockwinners Market Radar for June 09, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:20 EDT Lululemon director Morfitt buys 4,800 common shares - In a regulatory filing, Lululemon director Martha Morfitt disclosed the purchase of 4,800 common shares of the company on June 8 at a price of $330 per share.

18:21 EDT Crowdstrike CEO: We're seeing a move towards enterprise ransomware - In an interview on CNBC's Mad Money, George Kurtz said ransomware as a service is a very fluid and dynamic market. It's an area of focus for Crowdstrike, he noted. "We're seeing a move towards enterprise ransomware. It has become big game hunting," he added. According to Kurtz, the company has over 11,000 clients and is "super proud" of its customer base.

17:35 EDT AMC Entertainment director Pawlus sells 15,379 class A shares - In a regulatory filing, AMC Entertainment director Kathleen Pawlus disclosed the sale of 15,379 class A common shares of the company on June 8 at a price of $55.5376 per share.

17:27 EDT Merck awarded $1.21B Army contract for antiviral MK-4482 - Merck was awarded a $1.21B firm-fixed-price contract for 1,696,629 treatment courses of the oral antiviral MK-4482. Bids were solicited via the internet with one received. Work will be performed in Kenilworth, New Jersey, with an estimated completion date of June 15, 2022. FY20 Coronavirus Aid, Relief and Economic Security, or CARES, Act funds in the amount of $1.21B were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:19 EDT Ranger Energy names Bill Austin interim CEO - Ranger Energy Services, Inc. announced that Darron Anderson is leaving the company after leading Ranger for the last four years. The Board of Directors has appointed the company's Chairman of the Board, Bill Austin, as interim CEO. The Board has engaged an executive search firm to assist with the recruitment of a new permanent CEO. Austin has served as a member of Ranger's Board of Directors since May 2017 and will continue to serve as Chairman of the Board of Directors while he serves as interim CEO. Austin has more than 40 years' experience in varying industries, including oilfield services. Austin currently serves as a member of the board of directors of Stallion Oilfield Services, a position he has held since October 2017, and was formerly a member of the board of directors of Nuverra Environmental Solutions, Inc. and Express Energy LLP. Austin served as Executive Vice President and Chief Financial Officer of Exterran Holdings from December 2011 until April 2014, and he also served as Senior Vice President and Director of Exterran GP, LLC from April 2012 until April 2014.

17:14 EDT GameStop says excited about emerging console cycle - Says York, Pennsylvania distribution center expected to be operational in Q4. Says operates 4,698 stores around the globe. Says remains excited about emerging console cycle and the company's future. Says experiencing strong sales in May. Comments taken from Q1 earnings conference call.

16:59 EDT Ezcorp buys 128 pawn stores in Mexico for $33.8M - EZCORP "announced that it has acquired 128 pawn stores in Mexico. The stores, operating under the name Cash Apoyo Efectivo, are principally located in the Mexico City metropolitan area and enjoy strong brand recognition in that market." The initial purchase price of $33.8M includes cash of $17.3M, 212,870 shares of the company's Class A Non-Voting Common Stock valued at $1.6M , and repayment of $14.9M of Cash Apoyo Efectivo's existing debt. The sellers will be entitled to additional payments of up to $4.6M over the next two years, contingent on the performance of the acquired stores.

16:40 EDT Artisan Partners reports AUM $172.9B as of May 31 - Separate accounts accounted for $88.9B of total firm AUM, while Artisan Funds and Artisan Global Funds accounted for $84B.

16:37 EDT GameStop receives request from SEC for documents on trading activity - In a regulatory filing, GameStop said that, on May 26, 2021, it received a request from the staff of the SEC for the voluntary production of documents and information concerning a SEC investigation into the trading activity in our securities and the securities of other companies. "We are in the process of reviewing the request and producing the requested documents and intend to cooperate fully with the SEC Staff regarding this matter," the company said. "This inquiry is not expected to adversely impact us."

16:33 EDT TC Energy confirms termination of Keystone XL Pipeline Project - TC Energy confirmed that after a comprehensive review of its options, and in consultation with its partner, the Government of Alberta, it has terminated the Keystone XL Pipeline Project. Construction activities to advance the Project were suspended following the revocation of its Presidential Permit on January 20, 2021. The company will continue to coordinate with regulators, stakeholders and Indigenous groups to meet its environmental and regulatory commitments and ensure a safe termination of and exit from the Project.

16:31 EDT Franklin Resources reports preliminary AUM $1.543T as of May 31st - Compared to $1.529T at April 30th.

16:25 EDT RH says global competitive environment more primed for disruption than NA - The company states: "We believe that RH has the potential to become a $20B to $25 billion global brand in its current form, and possibly larger if aspects of our ecosystem become meaningful revenue streams. Our view is the competitive environment globally is more fragmented and primed for disruption than the North American market, and there is no direct competitor of scale that possesses the product, operational platform, and brand of RH. Our global expansion begins in the Spring of 2022 with the opening of RH England, The Gallery at Aynhoe Park, a 73 acre historic estate designed in 1615 by Sir John Soane, arguably one of the most respected and celebrated architects of his time. RH England will feature The Aynhoe Architectural Library, The Aynhoe Organic Gardens, The RH Restaurant & Orangery, and The RH Champagne & Caviar Cellar among other unique experiences. Pending reopening plans for France, our goal is to open RH Paris, The Gallery on the Champs-Elysees in the Fall of 2022. Customers will arrive through magnificent 18 foot gates and walk down a decomposed granite path lined with majestic hedges that lead to a garden courtyard where you encounter 18 foot brass doors that open to a six floor atrium connected by traversing brass staircases and a glass elevator. RH Paris will include a restaurant overlooking the gardens inspired by the Grand Palais, a sparkling Champagne and Caviar Bar on the top floor, and a romantic rooftop garden where you can sip an RH Bellini while enjoying views of the Eiffel Tower. In total we have secured five locations in Europe including London, Munich and Dusseldorf, and are in final lease negotiations for an additional five locations which will open over the next two to three years."

16:24 EDT Boyd Gaming and Hawaiian Holdings partner for loyalty program - Boyd Gaming (BYD) and Hawaiian Airlines (HA) have entered a strategic partnership to allow members to earn benefits and rewards with Boyd Gaming's B Connected player loyalty program and the carrier's HawaiianMiles program. The partnership provides customers with greater access to B Connected's selection of reward tiers, exclusive player benefits and memorable entertainment experiences, as well as more ways to earn and use HawaiianMiles.

16:23 EDT Twitter appoints Mimi Alemayehou to board of directors, Jesse Cohn to step down - Twitter announced the appointment of Mimi Alemayehou to the Company's Board of Directors as a new independent director, effective immediately. In connection with Alemayehou's appointment, Jesse Cohn will be stepping down after an important year on the Board. As one of Twitter's largest shareholders, Elliott Investment Management will continue to engage with members of the company's senior management team and Board, facilitated by the Information Sharing and Engagement Agreement the company entered into with Elliott.

16:22 EDT Lakeland Industries provides update on COVID-19 impact - The company said, "We anticipate that impact of COVID-19 on sales in the U.S., Canada, and Europe will be largely exhausted by the end of Q2FY21, leaving only lesser levels of pandemic demand in developing regions of the world like India, Vietnam, and some parts of South America. We believe that surge related demand will continue to decline in the second half of FY22 and will be largely over by the end of FY22. Lakeland has responded accordingly by scaling operational activities to address demand where it originates around the world and by accelerating our marketing efforts for the resumption of industrial economic growth which has been clearly evident over the past two quarters. We used COVID-19 to our advantage as a catalyst for transformation. At the end of the first quarter of fiscal 2022, we have demonstrated resiliency in our operations and sustainability of our financial performance. Continued investments in our IT systems, data-centric planning processes, and organic growth initiatives are expected to drive ongoing improvements in productivity, efficiencies, and profitability. These aspects of our business should be complemented by the inorganic growth opportunities, such as business acquisitions, that we are now pursuing or intend to pursue."

16:20 EDT Invesco reports preliminary AUM $1.5T as of May 31 - An increase of 3.2% versus previous month-end. Total net inflows were $31.9B.

16:19 EDT Horizon Technology names Daniel Devorsetz as COO - Horizon Technology announced that it has appointed Daniel Devorsetz as COO, effective immediately. In addition, Devorsetz has concurrently been appointed as COO of Horizon's external investment advisor, Horizon Technology Finance Management. He currently serves as Chief Investment Officer for both Horizon and the Advisor, and will continue in those roles. He reports to Horizon President Gerald Michaud. Devorsetz joined HTFM in 2004 as Vice President, Credit, responsible for credit underwriting and portfolio management. He authored the policies and developed the tools and systems used by the team to structure, underwrite, and track its investments. Devorsetz was promoted to Chief Credit Officer in 2008 and named Chief Investment Officer in 2014. In recent years, his efforts have further enhanced Horizon's industry leading business development, credit operations and portfolio management functions.

16:17 EDT VIA Optronics partners with SigmaSense over new touch sensing solutions - VIA Optronics has formed a strategic partnership with SigmaSense, a player in touch sensing performance. As part of the strategic partnership, VIA has made a financial investment into SigmaSense and expanded their collaboration to develop new touch solutions for automotive applications, industrial displays and consumer electronics. "We are excited to announce our expanded collaboration and investment in SigmaSense. Combining the SigmaSense technology with our metal mesh touch capabilities will not only allow us to offer enhanced touch resolution and quality, we will also be able to provide new and exciting touch functionalities," said Jurgen Eichner, CEO & Founder of VIA. "With SigmaSense, we can deliver next level interactive user experiences while also applying new innovations across industries, from the consumer market to the high end automotive and industrial markets."

16:14 EDT Akamai director Ford sells 9,550 common shares - In a regulatory filing, Akamai director Monte Ford disclosed the sale of 9,550 common shares of the company on June 8 at a price of $117.29 per share.

16:14 EDT IAC reports May Angi Inc. total revenue up 7% from last year - As part of its May monthly metrics disclosure, IAC also reports Dotdash revenue up 67%, and its Search business revenue up 45% from last year. Emerging & Other revenue was up 44% from last year. Reference Link

16:13 EDT GameStop reports May sales up 27% - The company said, "GameStop is continuing to suspend guidance at this time; however, it believes total net sales is the most appropriate metric to evaluate performance at this time. The Company's second quarter sales trends continue to reflect momentum, with May total sales increasing approximately 27% compared to last year."

16:09 EDT GameStop appoints Matt Furlong as CEO, Mike Recupero as CFO - GameStop (GME) announced that it has appointed Matt Furlong as CEO and Mike Recupero as CFO. Furlong and Recupero join from Amazon (AMZN), where they each held senior roles and oversaw various growth initiatives during their respective tenures. Furlong's start date is June 21 and Recupero's start date is July 12. Furlong has experience implementing growth strategies across global geographies and product categories. Most recently, he was a Country Leader and oversaw Amazon's Australia business during a period of growth. Recupero is a technology industry finance executive, who spent more than 17 years at Amazon supporting growth across global geographies and product categories. He most recently served as CFO of the North American Consumer business after serving as CFO of Prime Video.

16:09 EDT GameStop appoints former Amazon executives as CEO and CFO

16:05 EDT Shake Shack names Katherine Fogertey CFO - Shake Shack announced that Katherine Fogertey has been appointed to serve as the company's Chief Financial Officer, effective June 14, 2021. Katie joins Shake Shack's executive leadership team and will be responsible for leading financial operations across the company, including accounting and control, financial planning and analysis, operations finance, investor relations and external reporting. Randy Garutti, CEO of Shake Shack, stated, "I am excited to welcome Katie to the Shake Shack leadership team as CFO. She brings extensive financial experience, knowledge of our brand and deep industry and capital markets insights. I know Katie will be a natural fit in our Shake Shack culture, and I'm looking forward to working with her and our entire team as our business enters a new phase of exciting growth ahead."

15:33 EDT Alcoa CFO says company on target for 'really strong' Q2 - Alcoa CFO William Oplinger said at the Deutsche Bank Global Basic Materials conference, "In April, if you recall, we gave some guidance around some of the short-term cost headwinds that we were seeing in the second quarter. And it was pretty clear, and anybody that wasn't familiar with it, should go back and look at the comments that we made back in April. Since that time, metal prices have markedly moved up. The trailing 15-day LME average for first quarter versus second quarter is roughly $400 per ton higher than what we saw in the first quarter. So we're expecting to have all that benefit of higher prices hit the bottom line. And so that's really favorable. Along with those higher prices you typically see in our industry, a little bit of cost creep, and we are looking at around $10 million to $20 million of some higher cost inflation in the second quarter. But that's just offsetting -- in a small part, offsetting the $400 a ton dropping to the bottom line. Taken in total, I think the second quarter will represent substantial improvement versus the first quarter. There will be substantial improvement versus the second quarter last year. So we're on target to have a really strong second quarter."

14:34 EDT Blizzard says online cross-play coming to 'Overwatch' - Activision Blizzard's (ATVI) Blizzard Entertainment said that cross-play, or the ability for players on different platforms to play with one another online at the same time, is coming to popular team shooter "Overwatch" soon. "Powered by the latest global Battle.net update, players from around the world can team up, regardless of their preferred platform," the company said in a blog post. "With the release of cross-play, all players will need to make a Battle.net account and link their appropriate console accounts. With the launch of Cross-Play, everyone who logs in to Overwatch by the end of 2021 will receive a Golden Loot Box to celebrate." All console players will be required to make a Battle.net account and link it to their console account. PC players do not need to take this step, as they already have a Battle.net account. "Overwatch" is currently playable on PC, Nintendo Switch (NTDOY), Xbox One (MSFT), and PlayStation 4 (SONY). Reference Link

13:37 EDT Virtu Financial slides as SEC said to undertake review of stock market structure - Shares of Virtu Financial (VIRT) are down $2.19, or 7%, to $29.27 in afternoon trading after the The Wall Street Journal's Dave Michaels reported earlier that the Securities and Exchange Commission is considering changing rules that govern how U.S. stocks are priced and traded, citing comments made by Chairman Gary Gensler. The SEC is looking at pricing incentives that trading venues use to attract orders, according to the report. Reference Link

13:18 EDT North American rail traffic rose 12.2% in week ended June 5, AAR says - he Association of American Railroad, AAR, reported U.S. rail traffic for the week ending June 5. For this week, total U.S. weekly rail traffic was 489,144 carloads and intermodal units, up 12.9% compared with the same week last year. For some rail traffic categories, percentage changes for the current week compared with the same week in 2020 are inflated because of the widespread shutdowns - and subsequent large reduction in rail volumes - that impacted many economic sectors last year at this time. North American rail volume for the week ending June 5, 2021, on 12 reporting U.S., Canadian and Mexican railroads totaled 324,161 carloads, up 15.4% compared with the same week last year, and 350,015 intermodal units, up 9.4% compared with last year. Total combined weekly rail traffic in North America was 674,176 carloads and intermodal units, up 12.2% North American rail volume for the first 22 weeks of 2021 was 15,389,692 carloads and intermodal units, up 12% compared with 2020.Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Genesee & Wyoming (GWR), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

12:10 EDT Volkswagen invests another $620M in Swedish battery partner Northvolt - Volkswagen is participating, with a contribution of $620M, in a financing round of its Swedish battery partner Northvolt AB with a total volume of $2.75B. The Group will thus maintain its stake in the company constant at about 20 percent. The funds are to be used for capacity expansion in the fields of production, recycling and research and development. Among other activities, Northvolt intends to expand the capacity of its Northvolt Ett gigafactory in Skellefteundefined, Northern Sweden from 40 GWh to 60 GWh per year, in order to meet higher demand from customers. Arno Antlitz, Group Board Member for Finance and IT: "With this investment, we are strengthening our strategic partnership with Northvolt as a supplier of sustainable battery cells which are produced using renewable energy and are comprehensively recyclable." Volkswagen had already invested about EUR900M in Northvolt in June 2019, acquiring about 20% of the shares in the company as well as a seat on the Board of Directors. The production of Volkswagen premium cells is to be concentrated at Skellefteundefined in cooperation with Northvolt. Production of these cells is due to start in 2023 and the annual capacity intended for Volkswagen is to be built up step-by-step to as much as 40 GWh.

12:04 EDT Vuzix to be added to Russell 3000 and Russell 2000 indexes - Vuzix announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, according to a preliminary list of additions posted June 4. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "We are pleased to see our shares added to the Russell Indexes, one of the leading market performance benchmarks in North America. We view this as an important milestone and one that demonstrates Vuzix' growing market leadership and enterprise value. At the same time, we feel this should help raise awareness and the appeal of Vuzix within the institutional investment community," said Vuzix CEO Paul Travers.

12:00 EDT Veritiv falls -12.7% - Veritiv is down -12.7%, or -$9.39 to $64.61.

12:00 EDT United Natural Foods falls -20.4% - United Natural Foods is down -20.4%, or -$8.29 to $32.33.

12:00 EDT Invesco Mortgage rises 23.0% - Invesco Mortgage is up 23.0%, or 81c to $4.36.

11:36 EDT Fluidigm announces Advanta SARS-CoV-2 Mutation Assay Panel for variant detection - Fluidigm said via Twitter that it is "Announcing the Advanta(TM) SARS-CoV-2 Mutation Assay Panel for use with saliva or extracted RNA, a reflex-free and #highthroughput solution to detect CDC and WHO identified #Variants of Concern when run concurrently with additional reagents sold separately. https://fluidigm.com" Reference Link

11:31 EDT Huntington Ingalls' shipbuilding unit plans to hire 3,000 full-time shipbuilders - Huntington Ingalls Industries' Ingalls Shipbuilding division plans to hire approximately 3,000 full-time shipbuilders as part of its future growth plan. "We are steadily adding new team members to our growing workforce," Ingalls Shipbuilding President Kari Wilkinson said. "Shipbuilding is a challenging, extremely rewarding and potentially life-changing career, and we are excited to offer so many full-time, stable, full-benefits opportunities to our community."

11:14 EDT Electronic Arts says Battlefield 2042 available now for pre-order - Electronic Arts and DICE announced Battlefield 2042, which they call "a groundbreaking first-person shooter set to revolutionize the modern multiplayer sandbox." Battlefield 2042 is available now for pre-order and is set to launch on retail and digital storefronts on October 22 for $59.99 on Xbox One, PlayStation4, and PC, and $69.99 on Xbox Series X and S and PlayStation5. Players who pre-order have three different editions to choose from, including the Battlefield 2042 Gold Edition for $89.99 on PC and $99.99 on console, or the Battlefield 2042 Ultimate Edition for $109.99 on PC or $119.99 on console. EA Play members get a 10-hour trial starting Oct 15, the company stated.

11:03 EDT Carlyle Group acquires majority stake in 1E; terms not disclosed - 1E, a company engaged in Unified eXperience Management, announced that The Carlyle Group has acquired a majority stake in the company. Founder and CEO, Sumir Karayi will retain a significant minority stake and remain CEO of the company. The financial details of the transaction were not disclosed. 1E's current senior management team will remain with the company. Cormac Whelan will be appointed as Chairman, as the business embarks on its next phase of growth.

10:52 EDT UPS at session lows, down nearly 5% as investor day meeting continues - As UPS continues to host its investor and analyst conference, shares have fallen to session lows. UPS shares are down $9.93, or nearly 5%, to $199.83 as of 10:51 AM EDT.

10:04 EDT Interactive Brokers CEO says to offer crypto trading by end summer - Interactive Brokers (IBKR) Chairman and CEO Thomas Peterffy said at the Piper Sandler Global Exchange and FinTech Conference when asked about cryptocurrency plans that "Customers certainly are asking for it, and we expect to be ready to offer it to them by the end of the summer." He added, according to a transcript of the event: "As to hurdles ... how do you keep your customers going to 100% sale. Think about it. How do you make it 100% sure that no one will steal their coins in spite of the fact that they are untraceable. We will find out more about this when we open for business at the end of the summer... We have done some work. It's not a huge amount of work, but we have been working on it for some time now. And as I said, we expect to be done by the end of the summer." In early trading, Coinbase (COIN) shares are fractionally lower following Peterffy's conference presentation.

10:00 EDT Clarivate falls -13.8% - Clarivate is down -13.8%, or -$4.51 to $28.30.

10:00 EDT United Natural Foods falls -17.8% - United Natural Foods is down -17.8%, or -$7.22 to $33.40.

10:00 EDT Ashford Hospitality rises 19.8% - Ashford Hospitality is up 19.8%, or $1.24 to $7.51.

09:56 EDT GEO Group trading resumes

09:47 EDT Clarivate falls -9.9% - Clarivate is down -9.9%, or -$3.27 to $29.55.

09:47 EDT United Natural Foods falls -12.7% - United Natural Foods is down -12.7%, or -$5.17 to $35.45.

09:47 EDT Ashford Hospitality rises 19.0% - Ashford Hospitality is up 19.0%, or $1.19 to $7.46.

09:46 EDT Geo Group joins meme stock rally as short squeeze play - Shares of Geo Group (GEO) are rallying after being talked about on Reddit's WallStreetBets forum as a possible short squeeze candidate. The stock in early trading is up 40%, or $2.56, to $8.92. CoreCivic (CXW), another operator of private prisons, is up 9% to $10.31.

09:34 EDT Crypto names recover as bitcoin price jumps over 4% - Shares of Marathon Digital (MARA) were up about 2% above $24 while Riot Blockchain rallied 2.5% above $25.80 at the open amid a rebound in bitcoin and other cryptocurrencies. Bitcoin is trading higher by about 4.5% just shy of $35,000 mark - the highest percentage increase since May 31st.

09:31 EDT Clean Energy has no plans to raise additional capital at this time - On June 8, Clean Energy Fuels disclosed that it sold 10.47M shares of common stock under its at-the-market equity offering program and exhausted the new ATM Program in full. In the aggregate, the company issued 22.8M shares of common stock and received gross proceeds of $199,999,720 pursuant to the new at-the-market program and the prior program. As previously disclosed, Clean Energy intends to use the net proceeds for developing and acquiring renewable natural gas production projects and building fueling stations to support contracted RNG fueling volume. The company said it has no plans to implement a new at-the-market equity offering program to raise additional capital at this time. Shares of Clean Energy are up 39% to $13.78 in early trading.

09:25 EDT UWM Holdings up over 9% on Reddit post highlighting 1% rate price cut - Shares of UWM Holdings are up about 9% in pre-market trading at $10.08 following a Reddit WallStreetBets group post highlighting the video made by the company's CEO on Facebook announcing a cut in rate prices of about 100bps. Reference Link

09:20 EDT Liquid Media announces LOI to acquire iGEMStv for up to 566,667 shares - Liquid Media Group announced the signing of a letter of intent to acquire iGEMStv which provides a curated platform of content recommendations, including movies, TV series and TV shows. Under the terms of the LOI, Liquid would acquire iGEMStv for up to 566,667 shares, and iGEMStv must achieve revenues totalling over $9.5M to trigger three of the four equal tranches. "We look forward to welcoming iGEMS into the Liquid business family. Their unique blend of machine learning, human curation and deep experience in the space drives content discoverability for consumer audiences seeking the very best content in all genres. At the same time, iGEMS would become yet another channel to help IP owners working with Liquid reach a wider audience," said Liquid CEO Ron Thomson. Under the terms of the LOI, Liquid proposes to acquire iGEMS for a total of up to 566,667 common shares of Liquid, which would be paid out to iGEMS investors across specific performance milestones in four equal tranches of 141,667 common shares each. The first tranche of Consideration Shares would be payable upon closing, with three remaining milestones triggered by iGEMStv revenues totaling $9.5M in the years ahead. Additional cash would be invested in iGEMS' ongoing operations, beginning with immediate availability of a secured bridge loan in the amount of $100,000, to be applied towards working capital, technology infrastructure and marketing. Final terms of the acquisition will be negotiated and memorialized in binding and definitive documentation to be entered into at or prior to closing. Completion of the acquisition is subject to customary due diligence, documentation provisions and any necessary share issuance requirements and approvals.

09:15 EDT National Retail Solutions, Koupon expand partnership - National Retail Solutions, a subsidiary of IDT, announced the expansion of its partnership with Koupon to significantly extend the reach of consumer packaged goods brands through independent C-stores. "We are excited to offer Koupon's CPG clients a robust, integrated suite of advertising and data offerings," said Eli Korn, Chief Operating Officer of NRS. "In-store coupons and promotions are significantly more effective when complemented by ads displayed on NRS' customer-facing digital screens that are viewed by over 60M eyeballs every month. Moreover, our actionable analytics platform provides CPG brands with unprecedented visibility into the impact of their promotions."

09:13 EDT Avadel Pharmaceuticals presents new clinical data from phase 3 REST-ON study - Avadel Pharmaceuticals announced new post hoc analyses of data from the completed pivotal Phase 3 REST-ON clinical trial of FT218. The data were presented in three separate posters at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. FT218 is currently under review at the Food and Drug Administration with a Prescription Drug User Fee Act target date of October 15, 2021. Highlights from the poster presentations are outlined below. Efficacy of FT218, a Once-Nightly Sodium Oxybate Formulation, by Narcolepsy Subtype: A Post Hoc Analysis from the REST-ON Study. FT218 demonstrated statistically significant improvement in excessive daytime sleepiness at all evaluated doses in patients with narcolepsy subtypes 1 and 2, with greater improvement in measures of EDS, including mean sleep latency on maintenance of wakefulness test and Clinical Global Impression-Improvement in overall condition, compared to placebo. A significantly greater percentage of patients with NT1 receiving FT218 were rated as much or very much improved on the CGI-I compared to placebo. A greater percentage of NT2 patients receiving FT218 were rated as much/very much improved at all three doses vs. placebo. Efficacy of FT218, a Once-Nightly Sodium Oxybate Formulation, by Stimulant Use: A Post Hoc Analysis from the REST-ON Study. FT218 demonstrated statistically significant improvement in EDS at all evaluated doses in narcolepsy patients with or without stimulant use, with improvement over placebo on MWT and CGI-I. More patients receiving FT218 were rated much/very much improved on CGI-I compared to placebo. Weight Loss with FT218, a Once-Nightly Sodium Oxybate Formulation for the Treatment of Narcolepsy: Post Hoc Analysis from REST-ON. Patients receiving FT218 experienced a significantly greater decrease in weight and body mass index from baseline to study end compared to placebo. Overall, 17.8% of patients receiving FT218 compared to 3.8% of patients receiving placebo experienced more than 5% weight loss.

09:11 EDT CynergisTek unit Redspin 1st group to pass DoD CMMC Level 3 certification - Redspin, a division of CynergisTek is the first organization to successfully pass the Cybersecurity Maturity Model Certification Level 3 certification as a Candidate CMMC Third Party Assessor Organization Specifically, Defense Contract Management Agency Defense Industrial Base Cybersecurity Assessment Center (DIBCAC) determined Redspin's security practices and processes met the requirements of CMMC Level 3 and, subsequently, the CMMC Accreditation Body has credentialed Redspin, as an Authorized C3PAO ready to conduct CMMC assessments. The United States Department of Defense is aiming to reduce the estimated $600B in cybercrime losses impacting the nation's military supply chain every year by requiring a third-party cyber security assessment of contractors with access to federal contract information and controlled unclassified information . With this authorization, Redspin can now work contractually with Organizations Seeking Certification to conduct assessments based on CMMC Levels 1-3. In the CMMC model, Defense Industrial Base ( contractors cannot negotiate on security - it becomes a mandatory requirement to secure or renew a DoD contract.

09:08 EDT Tecogen announces two manufacturers' representative agreements - Tecogen announces manufacturers' representative agreements with two refrigeration equipment sales companies to support sales of Tecofrost refrigeration systems in parts of the western United States and Canada. I-REFCO, located outside of Seattle, WA, will have exclusive sales rights for Tecofrost in Washington, Oregon, Idaho, Montana, Wyoming, Utah, and Alaska, as well as in the Canadian provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Yukon, Nunavut, and Northwest Territories. Tecogen also established Refrigeration Equipment Specialist as the Tecofrost manufacturers' representative in California, Nevada, Arizona, and Hawaii.

09:07 EDT Booz Allen gets$190M IT engineering services support contract from NIWC Pacific - The Enterprise Communications and Networks ECN, Division of Naval Information Warfare Center Pacific NIWC Pacific, awarded Booz Allen Hamilton a contract with a potential value of $189.9M over five years, to provide a complete range of engineering, technical, cyber, and programmatic services. The work will support networking, communications, and computer systems around the world in service to the Navy's Program Executive Office Digital and the Naval Enterprise Networks Program Office, Program Management Warfare 205. The ECN Division plays a central role in the engineering and deployment of services and capabilities for Navy Enterprise Networks. This includes both the Navy Marine Corps Intranet ( and Base-Level Information Infrastructure/Outside Continental United States Navy Enterprise Network (BLII/ONE-Net). Together, these networks drive the execution of the Navy's vision for Information Warfare Dominance and Information Superiority through Modernization, Innovation, and Defense.

09:06 EDT Atossa Therapeutics announce final data from phase 2 Endoxifen study - Atossa Therapeutics announced the following final data from its Phase 2 clinical study of oral Endoxifen administered in the "window of opportunity" between diagnosis of breast cancer and surgery. Primary Endpoint Met: Reduction in Ki-67 was achieved. Ki-67, a common measure of tumor cell activity, was reduced from an average of 25.6% at screening to 6% on the day of surgery, a 65.1% reduction. Ki-67 was reduced below 25% for all patients, which is potentially clinically meaningful because studies by others have shown that a reduction below 25% improves long term survival. Secondary Endpoints Were as Follows: Safety and tolerability: All adverse events were mild and considered related to the study drug. There were no abnormal laboratory findings and no differences in vital signs, physical examinations and ECGs. Based on these results, Endoxifen was considered safe and well tolerated in this study. No adverse events led to discontinuation of the study. Other Results: Estrogen receptor expression decreased from 100% at screening to 88.6% on the day of surgery and progesterone receptor expression increased from 84.3% at screening to 92.9% on the day of surgery. No correlation between Ki-67 expression and Endoxifen levels was observed.

09:02 EDT Sintx Technologies to join Russell Microcap Index - SINTX Technologies announced today it has joined the Russell Microcap Index. SINTX became a member of the Russell Investments family of U.S. indexes upon its official reconstitution, made effective on June 4.

09:01 EDT Esports Technologies launches enhanced wagering platform in Brazil - Esports Technologies announced the launch of its international consumer platform, Gogawi, in Brazil. Gogawi.com, which recently also launched in Japan and Thailand, is an immersive betting destination offering wagering on esports tournaments and matches. Brazil represents Gogawi's first introduction to the Latin American market. Brazil is Latin America's leading gaming market and is expected to continue growing rapidly with total gaming revenue predicted to reach $1.17B by 2023. Esports Technologies relaunched Gogawi in March.

08:58 EDT Katapult completes business combination with FinServ Acquisition - Katapult Holdings and FinServ Acquisition announced that they have completed their previously announced merger. The business combination was approved at a special meeting of stockholders of FinServ on June 7, 2021, and closed today, June 9, 2021. The combined company now operates as Katapult Holdings and Katapult's common shares and warrants will begin trading on the Nasdaq Stock Market under the ticker symbols "KPLT" and "KPLTW", respectively, starting tomorrow, June 10, 2021. Orlando Zayas, CEO of Katapult, stated, "Taking our company public is a testament to the hard work and dedication of the entire Katapult team. We would like to thank the FinServ team for their belief in our success, and we look forward to their continued partnership as stockholders and members of our Board. We are thrilled to embark on this next stage in our company's history and excited to see the opportunities ahead of us for strong growth and long-term value creation."

08:52 EDT Extended Stay America urges sharholders to vote for proposed sale - Extended Stay America and its paired-share REIT, ESH Hospitality published a letter strongly urging its shareholders to vote "FOR" the transaction with funds managed by Blackstone Real Estate Partners(BX) and Starwood Capital at the ESA Special Meeting which will be held Friday, June 11, 2021. The letter stated, "Shareholders should seriously consider the meaningful downside risk to the share price - recognized by independent third parties - if the transaction is not approved... Absent a deal, shares of STAY have the potential to trade into the $15-$16 range temporarily, roughly 24% lower than the proposed offer, in our view... And the risk of value destruction under an independent approach governed by Tarsadia is high... The $20.50 per paired share offer delivers a meaningful premium to shareholders across multiple time horizons and values our paired shares at a 59% premium to their pre-pandemic value."

08:49 EDT Biocept, and CLEARED4 team to manage testing reporting for Biocept customers - Biocept and CLEARED4 have partnered to develop a system for tracking and managing COVID-19 testing requirements and test results for Biocept customers. The new service will leverage CLEARED4's comprehensive health platform, allowing organizations to incorporate customized protocols and requirements for testing students, employees and others. The platform will integrate results from Biocept's RT-PCR-based COVID-19 testing in real-time, and administrators will be able to monitor the program and results for their organizations via a secure dashboard.

08:45 EDT FIS announces Mark Hawkins has joined the company's Board - FIS announced that Mark J. Hawkins has joined the company's Board of Directors. Mr. Hawkins is currently the President and Chief Financial Officer Emeritus at Salesforce.com, a leading provider of enterprise cloud computing solutions, a position he has held since February 2021. He previously held the positions of President and Chief Financial Officer at Salesforce.com. Prior to Salesforce.com, Mr. Hawkins served as Executive Vice President and Chief Financial Officer at Autodesk, Inc., a provider of three-dimensional design, engineering and entertainment software; Chief Financial Officer and Senior Vice President, Finance & IT, at Logitech International SA, a provider of personal computer and tablet accessories; and held various finance and management roles at global technology companies Dell Inc. and Hewlett-Packard Company.

08:45 EDT Arena Pharmaceuticals receives orphan drug designation for etrasimod from FDA - Arena Pharmaceuticals announced that the FDA has granted orphan drug designation status to etrasimod, a selective, once-daily, oral sphingosine 1-phosphate, or S1P, receptor modulator, for the treatment of eosinophilic esophagitis, or EoE. Etrasimod is being investigated in the Phase 2b VOYAGE trial, a randomized, double-blind, placebo-controlled trial, with a primary efficacy measurement at week 16 and a secondary efficacy analysis at week 24, to assess the safety and efficacy of 1 mg and 2 mg etrasimod in approximately 100 participants with EoE.

08:40 EDT Foresight expands autonomous Ag equipment market with QuadSight Prototype Sale - Foresight Autonomous Holdings announced the sale of a prototype of its QuadSight four-camera vision system to a leading global manufacturer of agricultural and construction equipment. The manufacturer will evaluate Foresight's stereo capabilities for use in agricultural machinery. This is a first prototype sale to the agricultural equipment market, which is already deploying stereo technology for autonomous driving and automatic operations to increase productivity and efficiencies for higher yields. Foresight's advanced thermal stereoscopic capabilities are designed to bring added value to precision agriculture and automated navigation, covering planting, harvesting and loading crops for shipment, especially in adverse weather and low-visibility conditions where other sensors are challenged.

08:39 EDT Mercer Park Brand Acquisition updates status of share redemptions, acquisition - Mercer Park Brand Acquisition, a Special Purpose Acquisition Company, announced that it expects that immediately prior to the closing of the Glass House Group Transaction it will have cash in the aggregate amount of approximately $195M before expenses and transaction fees, which includes the previously announced private placement transactions totaling $135M expected to close concurrently with the Glass House Group Transaction. A total of 11,786,249 additional class A restricted voting shares were deposited for redemption by the June 2, 2021 and not validly withdrawn prior to the June 7, 2021 deadlines.

08:37 EDT Scansource appoints Rachel Hayden as Chief Information Officer - ScanSource announced the appointment of Rachel Hayden as Senior Executive Vice President and Chief Information Officer effective June 7, 2021. In this role, Hayden will lead the planning, implementation and execution of the company's global IT strategy. She will report directly to ScanSource Chairman and CEO, Mike Baur. Hayden brings impressive expertise to ScanSource, including leading complex, enterprise-wide programs. Hayden joins ScanSource from Just Born, Inc., where she served as the company's Chief Information Officer with direct responsibility for corporate and IT strategic planning, operations, and security. She previously spent five years with Berry Plastics in multiple roles, including Senior Director of IT, Global

08:36 EDT IAA, Dealertrack expand pact for electronic registration and title to Ohio - IAA announces an enhanced strategic agreement with Dealertrack to provide electronic registration and titling services in Ohio through facilitating the digital transfer of total loss titles. The agreement is announced as the global COVID-19 health crisis continues the acceleration of digitization efforts across the automotive industry, which faces yet another challenging year ahead due to the ongoing impacts of inventory shortages. These digital capabilities will be essential for dealerships to meet consumer expectations of completing more of the shopping experience online, as more than three quarters of today's shoppers are open to the idea of buying a vehicle completely online.1 The enhanced capabilities offered by IAA and Dealertrack will connect consumers, dealerships, and insurers in Ohio for a more efficient, more profitable electronic total loss title processing experience.

08:33 EDT Victory Capital announces intentions to enter cryptocurrency market - Victory Capital (VCTR) announced that its wholly owned investment adviser, Victory Capital Management, has established exclusive agreements with both Nasdaq (NDAQ) and crypto-focused asset manager Hashdex in advance of plans to enter the cryptocurrency market. Victory Capital will be the exclusive sponsor of private placement funds and other vehicles for U.S. investors, based on the Nasdaq Crypto Index, or NCI, a multi-coin crypto index co-developed by Nasdaq and Hashdex. Victory Capital plans to launch a private fund for accredited investors that will track the NCI. Additionally, Victory Capital will be offering private funds that track the Nasdaq Bitcoin Reference Price Index as well as the Nasdaq Ethereum Price Index. Hashdex will provide its trading and asset management expertise to each of these products.

08:32 EDT XpresSpa set to join Russell Microcap Index - XpresSpa announced that the company is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution according to a preliminary list of additions posted on June 4. Joining the index would become effective after the US market opens on June 28.

08:31 EDT Chinook Therapeutics promotes Frohlich to COO, King to CSO - Chinook Therapeutics announced that Tom Frohlich, chief business officer, has been promoted to chief operating officer, or COO, of Chinook and Andrew King, D.V.M, Ph.D., head of renal discovery and translational medicine, has been promoted to chief scientific officer, or CSO, of Chinook. In his role as COO, Tom will oversee Chinook's business development, CMC, quality, new product planning, program management and program team leadership functions. Tom co-founded and joined Chinook in January 2019 as chief business officer. In his role as CSO, Andrew will oversee the discovery research, non-clinical development and translational medicine teams. Andrew joined Chinook in May 2019 as head of renal discovery and translational medicine.

08:28 EDT Intercept appoints Berrey as President of Research & Development, CMO - Intercept Pharmaceuticals (ICPT) announced the appointment of M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer, or CMO. Dr. Berrey was most recently President and Chief Executive Officer at Chimerix (CMRX).

08:20 EDT Energous, Atmosic achieve interoperability for RF energy harvesting technology - Energous and Atmosic Technologies announced they have achieved the industry's first interoperability for radio frequency, or RF, energy harvesting technology. The interoperability combines Energous' WattUp RF-based wireless charging technology and Atmosic's M3 Series chipset - the company's energy harvesting technology that captures RF power - which together open up the market for wireless charging up to two meters away for connected solutions.

08:16 EDT SPI Energy subsidiary starts production on third-generation drivetrain products - Phoenix Motorcars, a group company of SPI Energy, started series production of its first third-generation drivetrain products. The first three units were completed out of the Ontario facility recently, ready for delivery to customers. The third-generation has the largest battery pack and longest range currently available in class 4 vehicles, lending itself to an extended range of body types. This includes shuttle buses, service trucks, utility trucks, flatbed trucks, cargo trucks and delivery options. The new liquid-cooled battery pack is modular, coming in 63, 94, 125 and 156kWh configurations, offering customers flexibility in terms of range, seating and payload capacity, and price.

08:09 EDT Valo Health, Khosla Ventures Acquisition to combine in $2.8B transaction

08:08 EDT Pulse Biosciences announces Health Canada approval for CellFX System - Pulse Biosciences announced the CellFX System has been approved by Health Canada for a Medical Device License for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Pulse Biosciences will now expand its controlled commercial launch of the CellFX System to select medical practices in Canada for the treatment of general dermatologic conditions, including sebaceous hyperplasia, seborrheic keratosis and cutaneous non-genital warts.Dermatologist Sheetal Sapra, MD of Toronto, Canada, is expected to begin participation in the CellFX System Controlled Launch program this month. "I am thrilled to be the first dermatologist in Canada to provide the clinical advantages of the CellFX System using NPS technology. I'm constantly seeking innovative ways to help my patients and I see an unmet need that the CellFX procedure can address in clearing challenging skin lesions like sebaceous hyperplasia, common warts and seborrheic keratosis," said Dr. Sapra, co-founder and director of the Institute of Cosmetic and Laser Surgery and Centre for Clinical Trials. "Health Canada approval marks an important corporate milestone in our regulatory strategy and enables the planned expansion of our CellFX System Controlled Launch program in Canada this quarter. This third regulatory approval, following FDA clearance and CE mark approval earlier this year, further validates our NPS technology and we are excited to bring our novel CellFX procedure to patients in Canada," said Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences. "We look forward to initiating our controlled launch program with leading aesthetic dermatologists in Canada, expanding to an estimated 80 practices participating across the US, EU and Canada."

08:07 EDT Orbital Energy subsidiary awarded $64M project by Fortune 100 energy company - Orbital Energy's wholly-owned subsidiary, Orbital Solar Services, has been awarded an Engineering, Procurement, and Construction contract to construct a 137 MW solar farm in Arkansas by a North American, Fortune 100 energy company. The project has an expected total value of over $64.0M. The Contract calls for OSS to design, engineer, and produce a utility-scale solar array to be delivered in early 2022. Under the Contract terms, OSS will provide full utility-scale EPC services, including substation construction.

08:06 EDT Assembly Biosciences to present data from HBV core inhibitor programs - Assembly Biosciences announced that three abstracts have been accepted for presentation during the International Liver Congress 2021, the Annual Meeting of the European Association for the Study of the Liver. During the meeting, data from Assembly Bio's three core inhibitor programs, vebicorvir, ABI-H2158, and ABI-H3733, will be featured in an oral presentation and two poster presentations. Oral Presentation OS-2299: Second generation hepatitis B virus core inhibitors ABI-H2158 and ABI-H3733 have enhanced potency and target coverage for both antiviral inhibition and covalently closed circular DNA establishment activities. Summary: VBR, 2158, and 3733 achieve plasma concentrations significantly above EC50 and protein-adjusted EC50 for antiviral activity. The next-generation compounds 2158 and 3733 show enhanced potency and exposures that cover cccDNA prevention at significant multiples above protein-adjusted EC50 at Cmin. Poster PO-1286: No emergent core inhibitor resistance in patients with chronic hepatitis B virus infection treated with vebicorvir in combination with a nucleos(t)ide reverse transcriptase inhibitor. Summary: Sequence analyses were conducted for virologically-suppressed patients with chronic HBV enrolled in the Phase 2 Study 201 and open-label extension Study 211 of VBR in combination with a nucleos(t)ide reverse transcriptase inhibitor who discontinued treatment. Overall, most patients did not have detectable core inhibitor substitutions; for patients harboring a core inhibitor substitution, no enrichment compared to baseline was observed after treatment was removed. Poster PO-482: Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleoside reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection. Summary: In the Phase 2 Study 201 and open-label extension Study 211, VBR+NrtI resulted in deep on-treatment virologic suppression. Stopping criteria were applied and eligible patients discontinued both VBR+NrtI. Discontinuation of VBR+NrtI treatment was well-tolerated, but sustained virologic response was not achieved. Further data analyses suggest core-related antigen level may be important in future discontinuation criteria. Other studies with VBR+NrtI in multi-drug combinations will evaluate potential finite treatment regimens.

08:05 EDT Vertex gets FDA approval forTRIKAFTA to treat children with mutations of CF - Vertex Pharmaceuticals announced the U.S. Food and Drug Administration approved expanded use of TRIKAFT, elexacaftor/tezacaftor/ivacaftor and ivacaftor, to include children with cystic fibrosis ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene or a mutation in the CFTR gene that is responsive to TRIKAFTA based on in vitro data. TRIKAFTA was previously approved by the FDA for use in people with cystic fibrosis 12 years and older with at least one copy of the F508del mutation or one copy of a mutation that is responsive in vitro. An additional dosage strength of TRIKAFTA tablets is now available (elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 75 mg and ivacaftor 75 mg) in connection with this approval. "Today's approval is a critical milestone in our efforts to deliver medicines that help treat the underlying cause of this devastating disease as early in life as possible," said Reshma Kewalramani, M.D., Chief Executive Officer and President, Vertex. "We can now reach approximately 1,500 newly eligible children in the U.S., and we continue to pursue approval for this expanded indication in other countries." Vertex completed a 24-week Phase 3 open-label, multicenter study which enrolled 66 children ages 6 through 11 years old with cystic fibrosis (CF) who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation to evaluate the safety, pharmacokinetics and efficacy of TRIKAFTA. The regimen was generally well tolerated, and safety data were similar with those observed in previous studies of patients ages 12 years and older. The full data from this study were recently published in American Journal of Respiratory and Critical Care Medicine. "Clinical experience with TRIKAFTA in patients 12 and older over the past 20 months has demonstrated this medicine has a meaningful and unprecedented clinical benefit for patients. I look forward to now being able to treat younger patients with this breakthrough medicine, including those who have not presented major signals of disease progression," said Terri Laguna M.D., M.S.C.S., Associate Director of the Cystic Fibrosis Center and Division Head, Pulmonary and Sleep Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago. "In addition to bringing TRIKAFTA to a younger patient population, patients not previously eligible for any CFTR modulator will now be able to access a treatment that targets the underlying cause of their disease." TRIKAFTA(R) is already approved

08:04 EDT Campbell Soup tracking to cumulative savings target of $850M by end of FY22 - Comments taken from Q3 earnings conference call.

08:03 EDT CME Group to launch micro treasury yield futures - CME Group will expand its suite of liquid U.S. Treasury futures and options with the introduction of four new Micro Treasury Yield futures contracts on August 16, pending regulatory review. These micro-sized contracts will provide market participants exposure to the yield of on-the-run Treasury securities. Micro 2-Year, Micro 5-Year, Micro 10-Year, and Micro 30-Year Yield futures will be sized at $10 per basis point of yield, and will be cash settled to newly created BrokerTec cash U.S. Treasury benchmarks. Average daily volume in CME Group's U.S. Treasury futures and options grew more than 30% year-over-year during both April and May, in response to increased hedging and trading activity. The contracts will be listed on and subject to the rules of the CBOT.

07:55 EDT Adaptive Biotechnologies publishes data on COVID-19 vaccine, T-Cell response - Adaptive Biotechnologies (ADPT) announced that immunoSEQ T-MAP COVID was used in the Nature study to measure the T-cell immune response elicited by the Johnson & Johnson (JNJ) COVID-19 vaccine in the context of multiple variants of SARS-CoV-2, including B 1.351 and B.1.1.7. The study provides further evidence that the T-cell response may contribute to protection from COVID-19. Adaptive's Technology was used to quantify T-cell expansion across all regions of the virus, demonstrating that the T-cell response is broad and unaltered by mutations that render vaccine-generated antibodies less effective. In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnson's vaccine experienced similar efficacy against the B.1.351 variant. To understand the mechanism of protection, the COV1001 phase 1/2 trial analyzed blood samples from 20 vaccinated individuals to measure antibody immune response and T-cell response against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants. Post-vaccination, results showed that the levels of neutralizing antibodies were diminished against the variants, but that the T-cell immune response was preserved, suggesting T cells may provide protection against these emerging strains. Results indicate T-cells may be an important correlate of protection and should be considered as an endpoint for vaccine clinical trials.

07:50 EDT Auxly Cannabis announces $15M bought-deal public offering - Auxly Cannabis announces that it has entered into an agreement pursuant to which ATB Capital Markets, as sole bookrunner, and Cantor Fitzgerald Canada, acting as co-lead underwriters of the offering, together with a syndicate of underwriters, will purchase 47,620,000 Units of the company, on a bought-deal basis at a price per Unit of 31.5c for gross proceeds of $15,000,300. A.G.P./Alliance Global Partners is acting as the sole U.S. sub-agent and financial advisor to the Company in connection with the Offering in the United States. Each unit shall be comprised of one common share of the company and one-half of one Common Share purchase warrant of the company. Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of 38c at any time up to 36 months from closing of the Offering. The company has granted the Underwriters an option to increase the size of the offering by up to an aggregate number of Units equal to 15% of the total number of Units issued under the offering, such underwriters' option being exercisable at any time and from time to time up to 30 days following the closing of the offering. The closing of the Offering is expected to occur on or about the week of June 14, or such later or earlier date as the underwriters and the company may agree upon, and is subject to the company receiving all necessary regulatory approvals, including the approval of the necessary securities regulatory authorities.

07:49 EDT Ballard Power and Gore partner for fuel cell growth - Ballard Power Systems and W. L. Gore announced a multi-year fuel cell supply agreement. Gore produced the first commercially-adopted membrane for passenger vehicles.

07:45 EDT Campbell Soup drops 7% to $45.50 after Q3 results miss, FY21 guidance cut

07:39 EDT KemPharm set to join Russell 3000 Index, Russell 2000 Index - KemPharm announced its expected addition to the broad-market Russell 3000 Index and the Russell 2000 Index in accordance with the 2021 Russell indexes annual reconstitution. KemPharm's anticipated inclusion in the Russell indexes will be effective after the U.S. market opens on Monday, June 28, 2021.

07:37 EDT Adamis Pharmaceuticals provides update on ZIMHI - Adamis Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for review the company's resubmitted New Drug Application for ZIMHI, which is its higher naloxone injection product candidate for the treatment of opioid overdose. Adamis received FDA correspondence relating to the company's NDA, stating that the Agency had completed its filing review and had determined that the NDA was sufficiently complete to permit a substantive review. The FDA also provided a target action date under the Prescription Drug User Fee Act of November 12, 2021. "We are pleased with the FDA's decision to accept for review our NDA for ZIMHI. I believe this underscores the need for additional treatment alternatives for narcotic overdose," said Dr. Dennis J. Carlo, President and CEO of Adamis Pharmaceuticals. "We look forward to working collaboratively with the FDA during the review process to support the case for approval of ZIMHI."

07:35 EDT Inozyme announces acceptance of first european CTA for phase 1/2 of INZ-701 - Inozyme Pharma announced the acceptance of its Clinical Trial Application, or CTA, from the National Agency for the Safety of Medicines and Health Products in France to allow initiation of its Phase 1/2 clinical trial of INZ-701, as a potential treatment for ABCC6 Deficiency. Inozyme plans to initiate its Phase 1/2 trial in mid-2021. This CTA was submitted and accepted as part of ANSM's Fast Track procedure designed to reduce processing times for clinical trial authorization requests for innovative medical products. "The acceptance of this CTA marks another important regulatory milestone for Inozyme and a key advancement for INZ-701 as a potential treatment for people living with ABCC6 Deficiency," said Axel Bolte, MSc, MBA, co-founder, president, and CEO of Inozyme Pharma. "We are well-positioned to execute on our planned clinical study and the notable level of interest from the ABCC6 Deficiency community underscores the urgent need for therapeutic options. I want to express my thanks to the team at Inozyme and our external collaborators, all of whom have been instrumental in our continued progress."

07:22 EDT Campbell Soup announces up to $250M share repurchase program - Effective immediately, the board of directors authorized a new anti-dilutive share repurchase program of up to $250M to offset the impact of dilution from shares issued under the company's stock compensation programs. The program has no expiration date, but it may be suspended or discontinued at any time. The company's March 2017 strategic share repurchase program remains suspended.

07:19 EDT MindMed CEO J.R. Rahn to step down, Robert Barrow to assume CEO role - Mind Medicine announces that J.R. Rahn, the company's co-founder and CEO, is stepping down as CEO and a director, and that its chief development officer, Robert Barrow, will assume the position of CEO with immediate effect. The company will also initiate a comprehensive search for a CEO, in which Barrow will be a candidate, and Rahn will advise the company during its leadership transition. The transition of the company's leadership team will enable the company to pursue aggressively its clinical development programs and development of its companion innovative digital technologies. Barrow previously served as director of Drug Development & Discovery at Usona Institute, where he led preclinical, clinical and regulatory development efforts for Usona's psychedelic drug candidates and was responsible for obtaining Breakthrough Therapy Designation for psilocybin in the treatment of Major Depressive Disorder.

07:11 EDT IMV Inc. appoints Jeremy Graff as Chief Scientific Officer - IMV announced the appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer, effective as of June 14, 2021. Dr. Graff brings over 20 years of experience in preclinical and clinical research and translational analysis for novel immune-activating therapeutics in oncology. "We are thrilled to add a seasoned scientist and industry leader like Jeremy to our team to help oversee this critical period of clinical development for maveropepimut-S," said Fred Ors, Chief Executive Officer at IMV. "Dr. Graff's prior expertise working on therapies that activate anti-cancer immunity will be incredibly valuable to IMV and we look forward to his leadership in advancing our scientific strategy." Dr. Graff stated, "IMV has an extremely promising technology platform and is at an exciting period for its lead drug candidate, maveropepimut-S. I am enthusiastic to join the team and help shape the development and registration strategy while exploring new opportunities for its platform."

07:08 EDT Castle Biosciences receives New York State Department of Health permit - Castle Biosciences announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test. DecisionDx-SCC is Castle's gene expression profile, or GEP, test designed to use a patient's tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors. Being a permitted laboratory in the state of New York allows patients in that state to access the dompany's molecular diagnostic tests, designed to provide actionable molecular information to inform patient care decisions.

07:08 EDT Cedar Fair announces Duff Milkie resigns as General Counsel - Cedar Fair Entertainment announced a change in its corporate leadership team. Duff Milkie has agreed to transition out of his role as Executive Vice President, General Counsel, and Corporate Secretary after nearly 14 years in the post. In order to facilitate this change, Milkie has resigned his officer positions effective immediately. As part of the transition, he will remain an employee until September 30, 2021, serving in a nonexecutive role. After the transition date, he will serve as an Of Counsel Advisor to the company through the end of February 2022. "I want to thank Duff for his tremendous leadership during a transformational period for our company," said Richard A. Zimmerman, Cedar Fair president and chief executive officer. "During his tenure, he established and then developed a highly talented legal team recognized for its business acumen and high standards of customer service. Duff also led the charge on external affairs, resulting in many successful development initiatives and public/private partnerships that have had an important impact on our Company and the communities we serve. Most notably, the Cedar Point Sports Center and the Bowling Green State University Resort and Attractions Management program will always serve as examples of Duff's vision, passion and tenacity. As he moves on to the next chapter of his professional career, we extend our deepest gratitude and respect for his many contributions to Cedar Fair."

07:05 EDT Shoreline Bioscience and BeiGene in pact to develop NK-based cell therapeutics - Shoreline Bioscience and BeiGene announced an exclusive worldwide strategic collaboration to develop and commercialize a portfolio of NK-based cell therapeutics with Shoreline's iPSC NK cell technology and BeiGene's research and clinical development capabilities for different malignancies...Under the terms of the agreement, Shoreline will receive an upfront cash payment of $45 million from BeiGene and will be eligible to receive additional R&D funding, milestone payments and royalties based upon the achievement of certain development, regulatory, and commercial milestones. In the multi-target collaboration, the companies have agreed to work jointly to develop cell therapies for four designated therapeutic targets, with an option to expand the collaboration at a future date. Clinical development will be led by BeiGene globally, with Shoreline responsible for clinical manufacturing. BeiGene will have commercial rights globally, with Shoreline having an option to retain U.S. and Canadian commercialization rights for two targets. In connection with the agreement, BeiGene has an option to acquire an equity stake in Shoreline in its next round of equity financing, subject to specified conditions.

07:04 EDT XPO Logistics expects to spin off GXO Logistics in Q3

07:03 EDT Broadridge acquires AdvisorStream, terms not disclosed - Broadridge announced that it has acquired AdvisorStream, a provider of digital engagement and marketing solutions for the global wealth and insurance industries. The acquisition expands Broadridge's front-to-back office wealth capabilities, positioning Broadridge to serve growth-oriented advisors and firms looking to attract and engage prospects and clients across key digital channels.

07:02 EDT XPO Logistics raises Q2 adjusted EBITDA view to at least $490M - XPO has increased its expectation for Q2 2021 adjusted EBITDA to at least $490M, driven by stronger-than-expected performance in its transportation segment. Consequently, the company has increased its outlook for full year 2021 adjusted EBITDA to at least $1.845B-$1.895B, compared with the prior guidance of $1.825B-$1.875B. The new range for 2021 adjusted EBITDA reflects a year-over-year increase of 32% to 36% above 2020, comprised of: 28% to 32% growth in adjusted EBITDA in the logistics segment and 32% to 36% growth in adjusted EBITDA in the transportation segment.

07:01 EDT Neptune Wellness announces licensing pact between Sprout Foods, CoComelon - Neptune Wellness announced a multi-year licensing agreement between its Sprout Foods organic baby and toddler foods and CoComelon, owned and operated by Moonbug Entertainment. The licensing agreement was brokered by Moonbug's North American Licensing Agency, UTA and includes all North America. Product is expected in the summer of 2021. Terms of the deal were not disclosed.

06:47 EDT Merck announces procurement agreement with U.S. for molnupiravir - Merck announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Through the agreement, if molnupiravir receives Emergency Use Authorization or approval by the U.S. FDA, Merck will receive approximately $1.2B to supply approximately 1.7M courses of molnupiravir to the United States government. Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to have more than 10M courses of therapy available by the end of 2021. Merck also plans to submit applications for emergency use or approval to regulatory bodies outside of the U.S. and is currently in discussions with other countries interested in advance purchase agreements for molnupiravir. Merck is committed to providing timely access to molnupiravir globally and intends to implement a tiered pricing approach based on World Bank data that recognizes countries' relative ability to finance their public health response to the pandemic. As part of its access strategy, Merck has also entered into non-exclusive voluntary licensing agreements for molnupiravir with established generic manufacturers to accelerate availability of molnupiravir in 104 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies.

06:42 EDT ContextLogic up 29% in pre-market as second highest trending name on StockTwits - Shares of ContextLogic are up another 29% at $15.05 in pre-market trading following yesterday's 50% rally. The stock is the second highest-trending ticker on StockTwits in terms of message volume this morning.

06:36 EDT Tanzanian Gold updates metallurgical test work at Buckreef Gold Project - Tanzanian Gold and its joint venture partner, The State Mining Company, have received updated and "highly favourable" metallurgical test results from the sulphide component of the Buckreef Gold Mine mineral resource. Three diamond core samples taken from the fresh rock of the Buckreef Gold deposit were submitted for the study. Intercepts and gold recoveries confirmed in the report include: 0.54 g/t Au over 78.88m - 94.1%; 19.4 g/t Au over 27.99m - 95.4%; 1.71 g/t Au over 52.53m - 85.3%. No refractory association of gold with arsenic sulphide was detected. Clean tailings, high probability of mine tailings not being acid generating. Further opportunities to improve gold extraction from MC03 have been identified through diagnostic leach testing.

06:35 EDT Target increases quarterly dividend 32.4% to 90c per share - The board of directors of Target has declared a quarterly dividend of 90c per common share, a 32.4% increase from the prior quarterly dividend of 68c. The dividend is payable Sept. 10 to shareholders of record at the close of business August 18.

06:32 EDT BiomX to present preclinical results with BX004 in cystic fibrosis at ECFS - BiomX announced that preclinical results with BX004 in Cystic Fibrosis will be presented at the 44th European Cystic Fibrosis Conference. ECFS will be held from June 9-12. "Our upcoming presentation at ECFS highlights the capability of our BOLT platform to design phage cocktail candidates that can efficiently and selectively target pathogenic bacteria," said Jonathan Solomon, CEO of BiomX. "In vitro results demonstrate that BiomX's phage cocktail, BX004, was able to penetrate biofilm and was efficacious in significantly reducing bacterial levels of Pseudomonas aeruginosa encased in biofilm, relative to two different antibiotics. Encouraged by these promising preclinical results, we look forward to advancing BX004 in CF to a Phase 1b/2a trial with results from Part 1 expected in the first quarter of 2022."

06:25 EDT Cathie Wood's ARK Investment bought 193K shares of Unity Software on Tuesday

06:24 EDT Cathie Wood's ARK Investment bought 189.9K shares of Trimble on Tuesday

06:17 EDT Baker Hughes and Air Products to collaborate on global hydrogen projects - Air Products (APD) and Baker Hughes (BKR) announced a strategic global collaboration to develop next generation hydrogen compression aimed at lowering the cost of production and accelerating the adoption of hydrogen as a zero-carbon fuel. Baker Hughes will provide Air Products with advanced hydrogen compression and gas turbine technology for global projects, including NovaLT16 turbines for Air Products' net-zero hydrogen energy complex in Edmonton, Alberta, Canada and advanced compression technology for the NEOM carbon-free hydrogen project in the Kingdom of Saudi Arabia.

06:07 EDT Caraway Therapeutics establishes collaboration with AbbVie - Caraway Therapeutics announced an exclusive, collaboration and option agreement with AbbVie to develop and commercialize Caraway's small molecule therapeutics targeting TMEM175, a potassium ion channel critical to lysosomal function implicated in both Parkinson's disease and other neurodegenerative disorders. TMEM175 is a compelling target with strong genetic support. Loss of function mutations in TMEM175 are associated with reduced lysosomal efficiency in a subpopulation of PD patients, that can manifest as earlier age of disease onset or elevated risk of dementia relative to idiopathic PD. Under this collaboration, Caraway will continue to advance proprietary small molecule TMEM175 modulators, leveraging Caraway's unique drug discovery platform and expertise in lysosomal biology and cellular clearance mechanisms, and combine with AbbVie's expertise in disease biology, clinical development, and global commercialization. Under the terms of the agreement, Caraway will receive an upfront cash payment of $17M. After Caraway completes certain pre-clinical research and development activities for the collaboration program, AbbVie has an option to license the program and proceed into IND-enabling studies, clinical development, and commercialization. Caraway is eligible to receive up to $267M in payments, including upfront and future option payments, and development milestones. Caraway is also eligible to receive additional regulatory and commercial milestones, tiered royalties on global commercial sales, and has the option to participate in product development in return for higher royalty rates.

06:05 EDT Air Products announces plan to build hydrogen energy complex in Alberta - Air Products and its subsidiary Air Products Canada, in conjunction with the Government of Canada and the Province of Alberta, announced a multi-billion dollar plan to build a new net-zero hydrogen energy complex in an effort to make Edmonton, Alberta the center of western Canada's hydrogen economy. Air Products began work in 2018 on the core of this energy complex in Edmonton, which will begin with a C$1.3B net-zero hydrogen production and liquefaction facility expected onstream in 2024. This project has been approved by Air Products' board, subject to final completion of the agreements contemplated in signed Memorandums of Understanding between Air Products and Canadian authorities, and with appropriate permit approvals. This development is consistent with Air Products' growth strategy of executing global megaprojects that enable a transition to a cleaner, more sustainable energy future. The project relies on an innovative combination of well-established technologies to jump-start an ambitious transition to carbon neutrality.

06:04 EDT SPX Corporation selling SPX Transformer Solutions to GE-Prolec Transformers - SPX Corporation (SPXC) has entered into a binding agreement to sell 100% of the issued and outstanding stock of its wholly-owned subsidiary, SPX Transformer Solutions, to GE-Prolec Transformers, a subsidiary of a joint venture between GE (GE) and Xignux S.A. for a cash purchase price of $645M. SPX anticipates that after taxes on a gain from the sale, net proceeds will be approximately $540M. The purchase price is subject to customary net working capital and similar adjustments at closing. The transaction is anticipated to close during the second half of 2021, subject to the satisfaction of typical closing conditions, including antitrust regulatory review. SPX is updating its 2021 guidance for the anticipated sale of SPX Transformer Solutions. SPX expects to account for the results of SPX Transformer Solutions as discontinued operations when it reports Q2 results in early August. SPX now anticipates FY21 Adjusted EPS of $2.17-$2.37 vs. prior guidance of $3.06-$3.26 and adjusted revenue of $1.25B, vs. prior guidance of $1.7B, and adjusted operating income margin of 11%-12%, consistent with prior guidance.

05:21 EDT Gol Linhas to acquire MAP Transportes Aereos for R$28M in cash, stock - GOL Linhas announced it has entered into an agreement to acquire MAP Transportes Aereos, or MAP, a Brazilian domestic airline with flight routes to regional destinations and Sao Paulo's Congonhas Airport. Founded in 2011, MAP is the fifth-largest Brazilian domestic airline, with a fleet of seven 70-seat ATRs that operate on routes in the Amazon region from the Manaus Airport and Brazil's South and Southeast regions from Congonhas, the country's largest domestic airport. The realization of this transaction will reinforce GOL's positioning in two of of its main bases, with growth of approximately 10% at CGH via the addition of 26 daily flights. Thus, the company will be able to serve new destinations connecting South America's largest city to historically underserved domestic markets, as the restrictions resulting from the pandemic are reduced or eliminated. GOL maintains its single-fleet fleet strategy to service these new routes in a cost-efficient and sustainable way. The company also has the additional flexibility to evaluate new aircraft types or partnerships that can service these regional markets more cost efficiently, with no future obligation as it relates to MAP's current fleet. The Company intends to offer new destinations and routes, complementary to its current network at Congonhas Airport, that will provide a wider range of flight options for passengers and greater convenience for clients. In addition to expanding to new routes, the company will provide a substantially higher number of seats per flight than currently available by MAP to these markets. The ATRs will be substituted for larger and more efficient aircraft, giving continuity to GOL's regional strategy, that operates on 23 Boeing 737-700s - a model that can be substituted with even more efficient aircraft in the future. MAP will be acquired for R$28M in cash and stock, to be paid upon satisfaction of all closing conditions, comprised of 100,000 GOLL4 shares at R$28 per share and R$25M in cash to be paid in twenty-four monthly installments. At closing, the company will assume up to R$100M of MAP's financial obligations. The transaction closing is subject to certain conditions precedent, including approvals and confirmations by Brazil's National Civil Aviation Agency and by Brazil's Administrative Council for Economic Defense..

05:09 EDT Ferrari appoints Benedetto Vigna as its CEO - Ferrari (RACE) announced the appointment of Benedetto Vigna as its CEO. Vigna will join Ferrari on September 1 from STMicroelectronics (STM), where he is currently president of its analog, micro-electromechanical systems and sensors group, its largest and most profitable operating business in 2020.